Tumor necrosis factor alpha signaling pathway components (TNF-alpha signaling pathway)

The Tumor necrosis factor alpha (TNF-alpha) signaling pathway is a fundamental signaling network that regulates immune responses, inflammation, and cell fate (StatPearls, 2023). It is triggered by the binding of the TNF-alpha cytokine to two distinct cell-surface receptors, TNFR1 and TNFR2, which are members of the TNF receptor superfamily (UniProt, 2024). TNFR1 is ubiquitously expressed and contains a death domain that can initiate either pro-survival NF-kappaB signaling or programmed cell death via apoptosis or necroptosis (PubMed, 2021). In contrast, TNFR2 is primarily found on immune and endothelial cells and lacks a death domain, typically promoting cell survival and tissue regeneration (Frontiers in Immunology, 2020). Overactivation of this pathway is a primary driver of chronic inflammatory conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (NIH, 2021). Consequently, the pathway is a major therapeutic target, with several approved biologics, such as adalimumab and infliximab, designed to neutralize TNF-alpha and mitigate tissue damage (PubChem, 2024). However, systemic blockade of TNF-alpha signaling is associated with significant safety concerns, most notably an increased susceptibility to serious opportunistic infections like tuberculosis and a potential risk of malignancy (FDA, 2023).

Other names

TNF signaling pathwayTumor necrosis factor-alpha pathwayTNF-alpha signaling cascadeTNF-alpha/TNFR signaling

Drugs targeting this pathway primarily function by neutralizing the soluble and transmembrane forms of the Tumor necrosis factor alpha cytokine or by competitively inhibiting its binding to its cognate receptors, TNFR1 and TNFR2, thereby preventing the activation of downstream pro-inflammatory and cell death cascades.